| embryonal rhabdomyosarcoma | ||||
| Disease ID | 451 |
|---|---|
| Disease | embryonal rhabdomyosarcoma |
| Integrated Phenotype | (Waiting for update.) |
| Text Mined Phenotype | HPO | Name | Sentences' Count(Total Phenotypes:8) HP:0009792 | Teratoma | 4 HP:0002664 | Neoplasia | 2 HP:0000160 | Small mouth | 1 HP:0030741 | Teratoma of the mediastinum | 1 HP:0010784 | Uterine tumor | 1 HP:0100616 | Testicular teratoma | 1 HP:0002859 | Rhabdomyosarcoma | 1 HP:0030731 | Carcinoma | 1 |
| Disease ID | 451 |
|---|---|
| Disease | embryonal rhabdomyosarcoma |
| Manually Symptom | UMLS | Name(Total Manually Symptoms:3) |
| Text Mined Symptom | (Waiting for update.) |
Manually Genotype(Total Text Mining Genotypes:0) |
|---|
| (Waiting for update.) |
All Snps(Total Genotypes:1) | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| snpId | pubmedId | geneId | geneSymbol | diseaseId | sourceId | sentence | score | Year | geneSymbol_dbSNP | CHROMOSOME | POS | REF | ALT |
| rs121913529 | 23615277 | 3845 | KRAS | umls:C0206656 | BeFree | A KRAS(G12D)-induced zebrafish embryonal rhabdomyosarcoma was then used to assess the therapeutic effects of the small molecules. | 0.000271442 | 2013 | KRAS | 12 | 25245350 | C | T,G,A |
GWASdb Annotation(Total Genotypes:0) | |
|---|---|
| (Waiting for update.) | |
GWASdb Snp Trait(Total Genotypes:0) | |
|---|---|
| (Waiting for update.) | |
Mapped by lexical matching(Total Items:0) |
|---|
| (Waiting for update.) |
Mapped by homologous gene(Total Items:0) |
|---|
| (Waiting for update.) |
Chemical(Total Drugs:1) | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| CUI | ChemicalName | ChemicalID | CasRN | DiseaseName | DiseaseID | DirectEvidence | PubMedIDs | ||
| C0206656 | bortezomib | D000069286 | - | rhabdomyosarcoma, embryonal | MESH:D018233 | therapeutic | 18342500 | ||
FDA approved drug and dosage information(Total Drugs:0) | |
|---|---|
| (Waiting for update.) | |
FDA labeling changes(Total Drugs:0) | |
|---|---|
| (Waiting for update.) | |